Review findings

e first disease-specific human trials of NAD+ augmentation for vascular outcomes Investigated NR effects on walking performance in PAD Targeted disease-specific vascular outcomes rather than biomarkers alone NAD+ augmentation with nicotinamide riboside in Parkinson's disease (NOPARK trial) , published in Cell Metabolism (Brakedal B et al., 2022): Phase II RCT testing NR 1000 mg/day in Parkinson's disease patients, showing increased cerebral NAD+ and some clinical improvements NR supplementation increased cerebral NAD+ levels measured by MRS Some improvements in MDS-UPDRS scores in the NR group Generally well tolerated in PD patients Related Reading # NAD+ research studies and evidence NAD+ dosing protocols NAD+ side effects profile MOTS-c research guide SS-31 research guide Stay current on NAD+ research We summarize new studies, safety updates, and dosing insights — delivered biweekly.

Definitive mapping of the 12 hallmarks of aging to specific peptide interventions including Epitalon, FOXO4-DRI, SS-31, MOTS-c, and NAD+.

Definitive mapping of the 12 hallmarks of aging to specific peptide interventions including Epitalon, FOXO4-DRI, SS-31, MOTS-c, and NAD+.

Definitive mapping of the 12 hallmarks of aging to specific peptide interventions including Epitalon, FOXO4-DRI, SS-31, MOTS-c, and NAD+.

Definitive mapping of the 12 hallmarks of aging to specific peptide interventions including Epitalon, FOXO4-DRI, SS-31, MOTS-c, and NAD+.

Restore access No thanks, continue reading Related Reading Comparison Epitalon vs NAD+ comparison Peptide 5-Amino-1MQ NNMT inhibitor that boosts NAD+ levels Article Hallmarks of aging peptide interventions How NAD+ works at the cellular level Overview of NAD+ benefits and applications Scientific Details Molecular Formula C21H27N7O14P2 Molecular Weight 663.43 Da CAS Number 53-84-9 What is NAD+? # NAD+ (nicotinamide adenine dinucleotide) is a coenzyme present in all living cells that serves as a central metabolic hub linking cellular energy production to signaling and repair processes.

olic assessment Liver enzymes (AST, ALT) When: 4-6 weeks Why: Monitor hepatic function during supplementation NAD+ metabolite panel (if available) When: 4-8 weeks Why: Assess NAD+ response to supplementation 💡 Key Considerations → IV infusion rate determines tolerability; start slow (1-2 mg/min) and titrate → Oral precursors (NR, NMN) bypass the poor oral bioavailability of intact NAD+ → Contraindication: Avoid during active cancer treatment, particularly with PARP inhibitors → Ensure adequate hydration before and during IV sessions Subscribe to unlock this content Get weekly peptide research summaries, new study alerts, and protocol updates — free.

Report an Error Compare NAD+ with Other Peptides NAD+ vs Epitalon NAD+ has clear advantages in evidence breadth, human data, accessibility, and multi-hallmark coverage.

NAD+: Complete Overview and Research Guide | Peptide Protocol Wiki Skip to main content 🧬 Peptide Protocol Wiki Peptides Side Effects New Learn Directory Tools Blog News About ⌘K ⌘K 🌱 New to Peptides?

Epitalon's evidence base needs independent validation to match NAD+'s international research standard. → Related Articles Research Review 14 min read Anti-Aging Peptides by Mechanism: Senolytics, Telomeres, Mitochondria, and Hormones Research review of anti-aging peptides organized by mechanism of action including senolytic peptides (FOXO4-DRI), telomere peptides (epitalon), mitochondrial peptides (SS-31, MOTS-c), tissue remodelers (GHK-Cu), and bioregulators (pinealon, thymalin).

Epitalon's evidence base needs independent validation to match NAD+'s international research standard. → Related Articles Research Review 14 min read Anti-Aging Peptides by Mechanism: Senolytics, Telomeres, Mitochondria, and Hormones Research review of anti-aging peptides organized by mechanism of action including senolytic peptides (FOXO4-DRI), telomere peptides (epitalon), mitochondrial peptides (SS-31, MOTS-c), tissue remodelers (GHK-Cu), and bioregulators (pinealon, thymalin).

Epitalon's evidence base needs independent validation to match NAD+'s international research standard. → Related Articles Research Review 14 min read Anti-Aging Peptides by Mechanism: Senolytics, Telomeres, Mitochondria, and Hormones Research review of anti-aging peptides organized by mechanism of action including senolytic peptides (FOXO4-DRI), telomere peptides (epitalon), mitochondrial peptides (SS-31, MOTS-c), tissue remodelers (GHK-Cu), and bioregulators (pinealon, thymalin).

ng fermentation studies, NAD+ has since been recognized as one of the most important molecules in biology.

Fatty acid oxidation: Beta-oxidation generates NADH at each cycle, linking lipid metabolism to NAD+ availability.

NAD+ dependence: Sirtuin activity is directly limited by NAD+ availability; declining NAD+ with age reduces sirtuin function, contributing to mitochondrial dysfunction, epigenetic dysregulation, and impaired stress responses.

NAD+ biosynthesis pathways De novo synthesis (kynurenine pathway): From dietary tryptophan via quinolinic acid to NAD+; a minor contributor to NAD+ pools in most tissues except the liver.

herapeutic areas, primarily through direct NAD+ administration (IV) and through oral precursors NMN and NR.

ti-Aging & Longevity Immune Support Epitalon Epitalon (Epithalone) is not FDA or EMA approved.

Substance use disorders IV NAD+ infusions have been used in addiction medicine clinics for decades, though controlled evidence is limited.

Is NAD+ FDA approved?

n established through dose-finding studies Whether raising blood NAD+ translates to meaningful tissue NAD+ increases in humans is incompletely characterized The relative efficacy of different NAD+ precursors (NMN vs NR vs niacin) has not been established in head-to-head trials Long-term safety data beyond 12 months is limited for all NAD+ augmentation strategies Publication bias may favor positive results, particularly in preclinical literature Key Research Findings # Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults , published in Nature Communications (Martens CR et al., 2018;

Mitochondrial & Cellular Energy Anti-Aging & Longevity Vascular & Cardiovascular SS-31 SS-31 (Elamipretide): Cardiolipin-targeting mitochondrial peptide.

Mitochondrial & Cellular Energy Weight Loss & Metabolism MOTS-c MOTS-c: Mitochondrial-derived exercise mimetic peptide.

Research into NAD+ replenishment through direct supplementation and precursors (NMN, NR) is an active area of clinical investigation for age-related diseases.

ion increased skeletal muscle NAD+ metabolites (NAAD, MeNAM) Anti-inflammatory transcriptomic signatures detected in muscle biopsies Downregulation of energy metabolism and mitochondrial pathways in transcriptome Effect of oral nicotinamide mononucleotide on clinical parameters and nicotinamide metabolite levels in healthy Japanese men , published in Endocrine Journal (Irie J et al., 2020;

e first disease-specific human trials of NAD+ augmentation for vascular outcomes Investigated NR effects on walking performance in PAD Targeted disease-specific vascular outcomes rather than biomarkers alone NAD+ augmentation with nicotinamide riboside in Parkinson's disease (NOPARK trial) , published in Cell Metabolism (Brakedal B et al., 2022): Phase II RCT testing NR 1000 mg/day in Parkinson's disease patients, showing increased cerebral NAD+ and some clinical improvements NR supplementation increased cerebral NAD+ levels measured by MRS Some improvements in MDS-UPDRS scores in the NR group Generally well tolerated in PD patients Related Reading # NAD+ research studies and evidence NAD+ dosing protocols NAD+ side effects profile MOTS-c research guide SS-31 research guide Stay current on NAD+ research We summarize new studies, safety updates, and dosing insights — delivered biweekly.

e first disease-specific human trials of NAD+ augmentation for vascular outcomes Investigated NR effects on walking performance in PAD Targeted disease-specific vascular outcomes rather than biomarkers alone NAD+ augmentation with nicotinamide riboside in Parkinson's disease (NOPARK trial) , published in Cell Metabolism (Brakedal B et al., 2022): Phase II RCT testing NR 1000 mg/day in Parkinson's disease patients, showing increased cerebral NAD+ and some clinical improvements NR supplementation increased cerebral NAD+ levels measured by MRS Some improvements in MDS-UPDRS scores in the NR group Generally well tolerated in PD patients Related Reading # NAD+ research studies and evidence NAD+ dosing protocols NAD+ side effects profile MOTS-c research guide SS-31 research guide Stay current on NAD+ research We summarize new studies, safety updates, and dosing insights — delivered biweekly.

300-1000 mg daily for oral precursors (NR/NMN) Frequency 1-2x weekly IV (loading), monthly (maintenance); daily oral Duration 4-8 week loading phase IV; ongoing for oral precursors 💊 Administration Route IV Schedule 1-2 times weekly during loading; monthly maintenance; daily for oral precursors Timing IV sessions require 2-8 hours in clinical setting; oral NR/NMN typically taken in the morning 📅 Cycle Duration 4-8 weeks IV loading; ongoing for oral supplementation Repeatable Yes Preparation & Storage Diluent: Normal saline (0.9% NaCl) 250-500 mL for IV Storage: Lyophilized powder at -20C; reconstituted solution use within 24 hours ⚗️ Suggested Bloodwork ( 5 tests) CMP with liver enzymes (AST, ALT) When: Baseline Why: Baseline hepatic function assessment CBC with differential When: Baseline Why: Baseline hematologic assessment Fasting glucose and insulin When: Baseline Why: Baseline metab

dose: 1000 mg · cycle: Cycle · route: oral · timing: morning · frequency: daily · reconstitution: reconstituted

DOI: 10.1507/endocrj.EJ19-0313): First-in-human study of oral NMN 250 mg/day in 10 healthy men demonstrating safety and increases in NAD+ metabolites without significant adverse effects NMN 250 mg single dose was safe and well tolerated Increased plasma NMN and NAD+ metabolite levels No clinically significant adverse effects observed NR-SAFE: a randomized, double-blind, placebo-controlled trial of high-dose nicotinamide riboside in healthy middle-aged and older adults , published in Nature Aging (Vreones M et al., 2023): Safety-focused RCT testing NR at 1000 mg twice daily (2000 mg/day) for 12 weeks in healthy adults, establishing safety and tolerability at the highest studied dose NR 2000 mg/day was well tolerated over 12 weeks No clinically significant adverse events attributed to NR Confirmed dose-dependent NAD+ metabolite elevation in blood Nicotinamide riboside supplementation to improve lower extremity function in peripheral artery disease (Kalil RS et al., 2023): RCT investigating NR supplementation in peripheral artery disease patients, representing one of th

dose: 250 mg · route: oral · duration: for 12 weeks · frequency: twice daily

olic assessment Liver enzymes (AST, ALT) When: 4-6 weeks Why: Monitor hepatic function during supplementation NAD+ metabolite panel (if available) When: 4-8 weeks Why: Assess NAD+ response to supplementation 💡 Key Considerations → IV infusion rate determines tolerability; start slow (1-2 mg/min) and titrate → Oral precursors (NR, NMN) bypass the poor oral bioavailability of intact NAD+ → Contraindication: Avoid during active cancer treatment, particularly with PARP inhibitors → Ensure adequate hydration before and during IV sessions Subscribe to unlock this content Get weekly peptide research summaries, new study alerts, and protocol updates — free.

dose: 2 mg · route: IV · frequency: weekly

DOI: 10.1016/j.celrep.2019.07.043): Open-label study in 12 aged men showing oral NR 1000 mg/day for 21 days increased skeletal muscle NAD+ metabolome and induced anti-inflammatory gene expression signatures NR supplementat

dose: 1000 mg · route: oral · duration: for 21 days

tivates sirtuins (SIRT1-7) involved in DNA repair, gene silencing, and metabolic regulation • Substrate for PARPs (poly-ADP-ribose polymerases) critical for DNA damage repair • Investigated for neuroprotective effects in neurodegenerative disease models • Modulates inflammatory pathways through CD38 and SARM1 signaling Community-Reported Side Effects Anecdotal ? 📋 Protocol Quick-Reference Anti-aging, cellular energy support, neuroprotection, and metabolic health research 💉 Dosing Amount 250-750 mg per IV session;

dose: 750 mg · route: IV

DOI: 10.1038/s41467-018-03421-7): Crossover RCT in 24 healthy older adults showing NR 1000 mg/day for 6 weeks safely raised blood NAD+ by ~60% and tended to reduce systolic blood pressure and aortic stiffness NR 1000 mg/day increased whole blood NAD+ approximately 60% over baseline Trend toward reduced systolic blood pressure (-2 mmHg) and aortic stiffness Well tolerated with no serious adverse events Nicotinamide riboside augments the aged human skeletal muscle NAD+ metabolome and induces transcriptomic and anti-inflammatory signatures , published in Cell Reports (Elhassan YS et al., 2019;

dose: 1000 mg · duration: for 6 weeks

Strongest evidence: NR oral supplementation reliably raises blood NAD+ levels in humans (multiple RCTs); safety profile established up to 2000 mg/day.

dose: 2000 mg · route: oral

The Chromadex NIAGEN trials showed sustained elevation of NAD+ at 300-1000 mg/day doses.

dose: 1000 mg

e first disease-specific human trials of NAD+ augmentation for vascular outcomes Investigated NR effects on walking performance in PAD Targeted disease-specific vascular outcomes rather than biomarkers alone NAD+ augmentation with nicotinamide riboside in Parkinson's disease (NOPARK trial) , published in Cell Metabolism (Brakedal B et al., 2022): Phase II RCT testing NR 1000 mg/day in Parkinson's disease patients, showing increased cerebral NAD+ and some clinical improvements NR supplementation increased cerebral NAD+ levels measured by MRS Some improvements in MDS-UPDRS scores in the NR group Generally well tolerated in PD patients Related Reading # NAD+ research studies and evidence NAD+ dosing protocols NAD+ side effects profile MOTS-c research guide SS-31 research guide Stay current on NAD+ research We summarize new studies, safety updates, and dosing insights — delivered biweekly.

dose: 1000 mg

e first disease-specific human trials of NAD+ augmentation for vascular outcomes Investigated NR effects on walking performance in PAD Targeted disease-specific vascular outcomes rather than biomarkers alone NAD+ augmentation with nicotinamide riboside in Parkinson's disease (NOPARK trial) , published in Cell Metabolism (Brakedal B et al., 2022): Phase II RCT testing NR 1000 mg/day in Parkinson's disease patients, showing increased cerebral NAD+ and some clinical improvements NR supplementation increased cerebral NAD+ levels measured by MRS Some improvements in MDS-UPDRS scores in the NR group Generally well tolerated in PD patients Related Reading # NAD+ research studies and evidence NAD+ dosing protocols NAD+ side effects profile MOTS-c research guide SS-31 research guide Stay current on NAD+ research We summarize new studies, safety updates, and dosing insights — delivered biweekly.

Start the 7-step beginner guide Peptides Side Effects New Directory Learn Tools Blog News About NAD+ 📋 Overview 🧬 Molecule 🔄 Similar ⚠️ Side Effects 💉 Dosing 🔬 Research 🚨 Risks 👥 Community 📊 Community Data Home Peptides NAD+ Anti-Aging & Longevity Cognitive Enhancement Mitochondrial & Cellular Energy phase2 NAD+ Also known as: NAD+, Nicotinamide Adenine Dinucleotide, NAD, Beta-Nicotinamide Adenine Dinucleotide, Coenzyme I, DPN, Diphosphopyridine Nucleotide Compare with 1 peptide Research compiled by Peptide Protocol Wiki 📅 Updated February 12, 2026 Unverified TL;DR NAD+ (nicotinamide adenine dinucleotide) is a critical coenzyme found in every living cell, essential for mitochondrial energy production, DNA repair, and cellular signaling.

DOI: 10.1507/endocrj.EJ19-0313): First-in-human study of oral NMN 250 mg/day in 10 healthy men demonstrating safety and increases in NAD+ metabolites without significant adverse effects NMN 250 mg single dose was safe and well tolerated Increased plasma NMN and NAD+ metabolite levels No clinically significant adverse effects observed NR-SAFE: a randomized, double-blind, placebo-controlled trial of high-dose nicotinamide riboside in healthy middle-aged and older adults , published in Nature Aging (Vreones M et al., 2023): Safety-focused RCT testing NR at 1000 mg twice daily (2000 mg/day) for 12 weeks in healthy adults, establishing safety and tolerability at the highest studied dose NR 2000 mg/day was well tolerated over 12 weeks No clinically significant adverse events attributed to NR Confirmed dose-dependent NAD+ metabolite elevation in blood Nicotinamide riboside supplementation to improve lower extremity function in peripheral artery disease (Kalil RS et al., 2023): RCT investigating NR supplementation in peripheral artery disease patients, representing one of th

tivates sirtuins (SIRT1-7) involved in DNA repair, gene silencing, and metabolic regulation • Substrate for PARPs (poly-ADP-ribose polymerases) critical for DNA damage repair • Investigated for neuroprotective effects in neurodegenerative disease models • Modulates inflammatory pathways through CD38 and SARM1 signaling Community-Reported Side Effects Anecdotal ? 📋 Protocol Quick-Reference Anti-aging, cellular energy support, neuroprotection, and metabolic health research 💉 Dosing Amount 250-750 mg per IV session;

What are the side effects of NAD+?

Reported side effects of NAD+ include nausea and gastrointestinal discomfort, flushing and warmth, headache.

Most reported side effects are mild and tran

DOI: 10.1038/s41467-018-03421-7): Crossover RCT in 24 healthy older adults showing NR 1000 mg/day for 6 weeks safely raised blood NAD+ by ~60% and tended to reduce systolic blood pressure and aortic stiffness NR 1000 mg/day increased whole blood NAD+ approximately 60% over baseline Trend toward reduced systolic blood pressure (-2 mmHg) and aortic stiffness Well tolerated with no serious adverse events Nicotinamide riboside augments the aged human skeletal muscle NAD+ metabolome and induces transcriptomic and anti-inflammatory signatures , published in Cell Reports (Elhassan YS et al., 2019;

Peptide Directory All Peptides Metabolic Anti-Obesity Anti-Aging Immune Hormonal View All Categories Directory Peptide Vendors Analytics Labs Side Effects Database Report a Side Effect Learn Start Here What Are Peptides?

Consult the detailed side effects profile for full information.

NAD+: Complete Overview and Research Guide | Peptide Protocol Wiki Skip to main content 🧬 Peptide Protocol Wiki Peptides Side Effects New Learn Directory Tools Blog News About ⌘K ⌘K 🌱 New to Peptides?

olic assessment Liver enzymes (AST, ALT) When: 4-6 weeks Why: Monitor hepatic function during supplementation NAD+ metabolite panel (if available) When: 4-8 weeks Why: Assess NAD+ response to supplementation 💡 Key Considerations → IV infusion rate determines tolerability; start slow (1-2 mg/min) and titrate → Oral precursors (NR, NMN) bypass the poor oral bioavailability of intact NAD+ → Contraindication: Avoid during active cancer treatment, particularly with PARP inhibitors → Ensure adequate hydration before and during IV sessions Subscribe to unlock this content Get weekly peptide research summaries, new study alerts, and protocol updates — free.

olic assessment Liver enzymes (AST, ALT) When: 4-6 weeks Why: Monitor hepatic function during supplementation NAD+ metabolite panel (if available) When: 4-8 weeks Why: Assess NAD+ response to supplementation 💡 Key Considerations → IV infusion rate determines tolerability; start slow (1-2 mg/min) and titrate → Oral precursors (NR, NMN) bypass the poor oral bioavailability of intact NAD+ → Contraindication: Avoid during active cancer treatment, particularly with PARP inhibitors → Ensure adequate hydration before and during IV sessions Subscribe to unlock this content Get weekly peptide research summaries, new study alerts, and protocol updates — free.

Restore access No thanks, continue reading Related Reading Comparison Epitalon vs NAD+ comparison Peptide 5-Amino-1MQ NNMT inhibitor that boosts NAD+ levels Article Hallmarks of aging peptide interventions How NAD+ works at the cellular level Overview of NAD+ benefits and applications Scientific Details Molecular Formula C21H27N7O14P2 Molecular Weight 663.43 Da CAS Number 53-84-9 What is NAD+? # NAD+ (nicotinamide adenine dinucleotide) is a coenzyme present in all living cells that serves as a central metabolic hub linking cellular energy production to signaling and repair processes.

Epitalon targets a hallmark (telomere attrition) that NAD+ does not directly address, making it a potential complement rather than competitor.

Report an Error Compare NAD+ with Other Peptides NAD+ vs Epitalon NAD+ has clear advantages in evidence breadth, human data, accessibility, and multi-hallmark coverage.

Epitalon's evidence base needs independent validation to match NAD+'s international research standard. → Related Articles Research Review 14 min read Anti-Aging Peptides by Mechanism: Senolytics, Telomeres, Mitochondria, and Hormones Research review of anti-aging peptides organized by mechanism of action including senolytic peptides (FOXO4-DRI), telomere peptides (epitalon), mitochondrial peptides (SS-31, MOTS-c), tissue remodelers (GHK-Cu), and bioregulators (pinealon, thymalin).

Epitalon's evidence base needs independent validation to match NAD+'s international research standard. → Related Articles Research Review 14 min read Anti-Aging Peptides by Mechanism: Senolytics, Telomeres, Mitochondria, and Hormones Research review of anti-aging peptides organized by mechanism of action including senolytic peptides (FOXO4-DRI), telomere peptides (epitalon), mitochondrial peptides (SS-31, MOTS-c), tissue remodelers (GHK-Cu), and bioregulators (pinealon, thymalin).

Epitalon's evidence base needs independent validation to match NAD+'s international research standard. → Related Articles Research Review 14 min read Anti-Aging Peptides by Mechanism: Senolytics, Telomeres, Mitochondria, and Hormones Research review of anti-aging peptides organized by mechanism of action including senolytic peptides (FOXO4-DRI), telomere peptides (epitalon), mitochondrial peptides (SS-31, MOTS-c), tissue remodelers (GHK-Cu), and bioregulators (pinealon, thymalin).

Epitalon's evidence base needs independent validation to match NAD+'s international research standard. → Related Articles Research Review 14 min read Anti-Aging Peptides by Mechanism: Senolytics, Telomeres, Mitochondria, and Hormones Research review of anti-aging peptides organized by mechanism of action including senolytic peptides (FOXO4-DRI), telomere peptides (epitalon), mitochondrial peptides (SS-31, MOTS-c), tissue remodelers (GHK-Cu), and bioregulators (pinealon, thymalin).

Epitalon's evidence base needs independent validation to match NAD+'s international research standard. → Related Articles Research Review 14 min read Anti-Aging Peptides by Mechanism: Senolytics, Telomeres, Mitochondria, and Hormones Research review of anti-aging peptides organized by mechanism of action including senolytic peptides (FOXO4-DRI), telomere peptides (epitalon), mitochondrial peptides (SS-31, MOTS-c), tissue remodelers (GHK-Cu), and bioregulators (pinealon, thymalin).

Epitalon's evidence base needs independent validation to match NAD+'s international research standard. → Related Articles Research Review 14 min read Anti-Aging Peptides by Mechanism: Senolytics, Telomeres, Mitochondria, and Hormones Research review of anti-aging peptides organized by mechanism of action including senolytic peptides (FOXO4-DRI), telomere peptides (epitalon), mitochondrial peptides (SS-31, MOTS-c), tissue remodelers (GHK-Cu), and bioregulators (pinealon, thymalin).

Epitalon's evidence base needs independent validation to match NAD+'s international research standard. → Related Articles Research Review 14 min read Anti-Aging Peptides by Mechanism: Senolytics, Telomeres, Mitochondria, and Hormones Research review of anti-aging peptides organized by mechanism of action including senolytic peptides (FOXO4-DRI), telomere peptides (epitalon), mitochondrial peptides (SS-31, MOTS-c), tissue remodelers (GHK-Cu), and bioregulators (pinealon, thymalin).

Epitalon's evidence base needs independent validation to match NAD+'s international research standard. → Related Articles Research Review 14 min read Anti-Aging Peptides by Mechanism: Senolytics, Telomeres, Mitochondria, and Hormones Research review of anti-aging peptides organized by mechanism of action including senolytic peptides (FOXO4-DRI), telomere peptides (epitalon), mitochondrial peptides (SS-31, MOTS-c), tissue remodelers (GHK-Cu), and bioregulators (pinealon, thymalin).

Epitalon's evidence base needs independent validation to match NAD+'s international research standard. → Related Articles Research Review 14 min read Anti-Aging Peptides by Mechanism: Senolytics, Telomeres, Mitochondria, and Hormones Research review of anti-aging peptides organized by mechanism of action including senolytic peptides (FOXO4-DRI), telomere peptides (epitalon), mitochondrial peptides (SS-31, MOTS-c), tissue remodelers (GHK-Cu), and bioregulators (pinealon, thymalin).

Peptide Protocol Wiki February 17, 2026 FOXO4-DRI Epitalon SS-31 + 6 more Guide 16 min read The Hallmarks of Aging: Which Peptides Target Which?

e first disease-specific human trials of NAD+ augmentation for vascular outcomes Investigated NR effects on walking performance in PAD Targeted disease-specific vascular outcomes rather than biomarkers alone NAD+ augmentation with nicotinamide riboside in Parkinson's disease (NOPARK trial) , published in Cell Metabolism (Brakedal B et al., 2022): Phase II RCT testing NR 1000 mg/day in Parkinson's disease patients, showing increased cerebral NAD+ and some clinical improvements NR supplementation increased cerebral NAD+ levels measured by MRS Some improvements in MDS-UPDRS scores in the NR group Generally well tolerated in PD patients Related Reading # NAD+ research studies and evidence NAD+ dosing protocols NAD+ side effects profile MOTS-c research guide SS-31 research guide Stay current on NAD+ research We summarize new studies, safety updates, and dosing insights — delivered biweekly.

e first disease-specific human trials of NAD+ augmentation for vascular outcomes Investigated NR effects on walking performance in PAD Targeted disease-specific vascular outcomes rather than biomarkers alone NAD+ augmentation with nicotinamide riboside in Parkinson's disease (NOPARK trial) , published in Cell Metabolism (Brakedal B et al., 2022): Phase II RCT testing NR 1000 mg/day in Parkinson's disease patients, showing increased cerebral NAD+ and some clinical improvements NR supplementation increased cerebral NAD+ levels measured by MRS Some improvements in MDS-UPDRS scores in the NR group Generally well tolerated in PD patients Related Reading # NAD+ research studies and evidence NAD+ dosing protocols NAD+ side effects profile MOTS-c research guide SS-31 research guide Stay current on NAD+ research We summarize new studies, safety updates, and dosing insights — delivered biweekly.

e first disease-specific human trials of NAD+ augmentation for vascular outcomes Investigated NR effects on walking performance in PAD Targeted disease-specific vascular outcomes rather than biomarkers alone NAD+ augmentation with nicotinamide riboside in Parkinson's disease (NOPARK trial) , published in Cell Metabolism (Brakedal B et al., 2022): Phase II RCT testing NR 1000 mg/day in Parkinson's disease patients, showing increased cerebral NAD+ and some clinical improvements NR supplementation increased cerebral NAD+ levels measured by MRS Some improvements in MDS-UPDRS scores in the NR group Generally well tolerated in PD patients Related Reading # NAD+ research studies and evidence NAD+ dosing protocols NAD+ side effects profile MOTS-c research guide SS-31 research guide Stay current on NAD+ research We summarize new studies, safety updates, and dosing insights — delivered biweekly.

Definitive mapping of the 12 hallmarks of aging to specific peptide interventions including Epitalon, FOXO4-DRI, SS-31, MOTS-c, and NAD+.

Definitive mapping of the 12 hallmarks of aging to specific peptide interventions including Epitalon, FOXO4-DRI, SS-31, MOTS-c, and NAD+.

Definitive mapping of the 12 hallmarks of aging to specific peptide interventions including Epitalon, FOXO4-DRI, SS-31, MOTS-c, and NAD+.

Definitive mapping of the 12 hallmarks of aging to specific peptide interventions including Epitalon, FOXO4-DRI, SS-31, MOTS-c, and NAD+.

Definitive mapping of the 12 hallmarks of aging to specific peptide interventions including Epitalon, FOXO4-DRI, SS-31, MOTS-c, and NAD+.

Definitive mapping of the 12 hallmarks of aging to specific peptide interventions including Epitalon, FOXO4-DRI, SS-31, MOTS-c, and NAD+.

Peptide Protocol Wiki February 13, 2026 Carnosine Epitalon FOXO4-DRI + 5 more You Might Also Like Related content you may find interesting Peptide Anti-Aging Epitalon Peptide Anti-Aging Carnosine Peptide Anti-Aging FOXO4-DRI Peptide Anti-Aging Humanin Table of Contents What is NAD+?

Epitalon's evidence base needs independent validation to match NAD+'s international research standard. → Related Articles Research Review 14 min read Anti-Aging Peptides by Mechanism: Senolytics, Telomeres, Mitochondria, and Hormones Research review of anti-aging peptides organized by mechanism of action including senolytic peptides (FOXO4-DRI), telomere peptides (epitalon), mitochondrial peptides (SS-31, MOTS-c), tissue remodelers (GHK-Cu), and bioregulators (pinealon, thymalin).